

Critical Importance of New Generation Government Engagement Navigating Government Healthcare Reforms and their impact in USA, Europe, Turkey & Emerging Markets

Yavuz Selim Silay MD, MBA

Co-Founder & CEO MAIN (MaQasid Angel Investors Network) Chairman, ICG (Istanbul Consulting Group), İstanbul, Turkey)

***Corresponding author:** Dr. Yavuz S. Silay Istanbul, Turkey, E-mail: drysilay@yahoo.com

Contact number: +90-531-5103369

Twitter account: @drysilay

Linked In account: <http://www.linkedin.com/in/yavuzsilay>

Abstract

Pharmaceutical, Biotech and Medical Device companies are constantly evaluating how decisions at the US, Europe, Turkey and emerging markets are taken at the federal and state level and how it will impact provider and patient access and coverage to their therapies.

To gain these critical insights, Government Affairs & Medical affairs teams require speaking with those on the frontlines of healthcare delivery - physicians, allied healthcare professionals, payers, and patients. New generation government engagement and commercial diplomacy approach developed by ICG (Istanbul Consulting Group) will be provided with unique cases.

Dr. Yavuz Selim SILAY a global leader and seasoned expert in Government engagement, Commercial Diplomacy, Corporate Communications, Government affairs & Medical Affairs will discuss how companies utilizing Government Affairs and Medical affairs teams should engage decision makers, payers, physicians and acquire these insights in a convenient, cost-effective, and compliant manner in this current changing global regulatory landscape. Current Trends in Physician Entrepreneurship in USA Europe Turkey and Emerging Markets will be provided with unique cases.

Keywords: Immune necrotizing; Glutaryl coenzyme; Auto immune diseases; Electro myography; Intravenous immunoglobulin

Biography

Yavuz is the Co-Founder & CEO of MAIN (MaQasid Angel Investors Network) & chairman of Istanbul Consulting Group. MAIN is the fastest growing global ethical angel investor network investing in technology in Emerging Markets. ICG (Istanbul Consulting Group) was founded in 2013 and provided guidance to the Turkish ministry of health as part of a World Bank project. Yavuz is currently the Co-Founder of Bio Cube İstanbul Bio entrepreneurship & Innovation Center and Corporate Communication Director of Archem Diagnostics. He previously managed the largest distributor of Siemens Healthcare in Turkey managing 250 employees and director of Avcılar Hospital R&D Center. Previously he worked as the Market Access & Health Policy Director for AIFD in Turkey.

Yavuz previously worked as the Vice President of Ipsen pharmaceutical and Director of Teva pharmaceutical in USA managing large clinical trials as well as Investigator Initiated Trials and developing relationships with Key Opinion Leaders. Previously, Yavuz was the Associate Director at KV Pharmaceuticals and Director in Clinical

Development department at Forest Laboratories.

Yavuz earned his MD from the Faculty of Medicine, University of Ankara in Ankara, Turkey. He completed a clinical internship at Baylor College of Medicine in Houston, followed by continued research training at The University of Texas MD Anderson Cancer Center in Houston. He recently completed his Executive MBA at the Olin Business School at Washington University in St. Louis. Yavuz currently resides with his wife Dr. Kamile Sılay and their two daughters and one son in Ankara, Turkey.

Conclusion

Pharmaceutical, Biotech and Medical Device companies are constantly evaluating how innovation management can be improved and managing expectations of Key opinion leaders.